Cart
sales@molnova.com
Losmapimod
CAS No. 585543-15-3
Losmapimod( GSK-AHAB | GW856553X | SB856553 | GW 856553X | SB 856553 )
Catalog No. M15150 CAS No. 585543-15-3
Losmapimod (GSK-AHAB, GW856553X, SB856553) is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 135 | In Stock |
|
| 50MG | 220 | In Stock |
|
| 100MG | 398 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 901 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLosmapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionLosmapimod (GSK-AHAB, GW856553X, SB856553) is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
-
DescriptionLosmapimod (GSK-AHAB, GW856553X, SB856553) is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively; displays no significant activity for p38γ, p38δ (<25% inhibition at 10 uM), and COX-2; significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation in rat model of cardiovascular disease.Ischemia Phase 3 Clinical(In Vitro):In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β).
-
In Vitro——
-
In VivoIn the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β).
-
SynonymsGSK-AHAB | GW856553X | SB856553 | GW 856553X | SB 856553
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38α|p38β
-
Research AreaCardiovascular Disease
-
IndicationIschemia
Chemical Information
-
CAS Number585543-15-3
-
Formula Weight383.4591
-
Molecular FormulaC22H26FN3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 58 mg/mL
-
SMILESO=C(C1=CC=C(C2=CC(C(NC3CC3)=O)=CC(F)=C2C)N=C1)NCC(C)(C)C
-
Chemical Name3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
SSK1
SSK1 is a compound that selectively kills senescent cells and is a precursor for β-galactosidase, which can reduce the inflammatory response of the body. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, and promote mitochondrial DNA damage in senescent cells.
-
Eudesmin
Eudesmin shows antiinflammatory neuritogenic anticonvulsant and sedative effects the mechanism of eudesmin may be related to up-regulation of GABAA and GAD65 expressions and anti-apoptosis of neuron the in brain.50 microM (+)-eudesmin can induce neurite outgrowth and enhance nerve growth factor (NGF)-mediated neurite outgrowth from PC12 cells by stimulating up-stream MAPK PKC and PKA pathways.
-
JNJ-49095397
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
